Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model

Código QR

Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model

Systems pharmacology:Predicting efficacy of novel anti-cancer drugs in colorectal cancer While cancer drug development relies on experimental tumor models for testing, results observed in these systems often fail to translate clinically. Kirouac et al. demonstrate how computational systems modelling...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniel C. Kirouac, Gabriele Schaefer, Jocelyn Chan, Mark Merchant, Christine Orr, Shih-Min A. Huang, John Moffat, Lichuan Liu, Kapil Gadkar, Saroja Ramanujan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/6bfc02d0615b4d33ac88a7be2e3e419b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
por: Shujun Han, et al.
Publicado: (2018)

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
por: Rengyun Liu, et al.
Publicado: (2018)

Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
por: Shujun Han, et al.
Publicado: (2018)

Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer
por: Keita Tanaka, et al.
Publicado: (2021)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
por: Maurício Fernando Silva Almeida Ribeiro, et al.
Publicado: (2021)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
por: Zaharie F, et al.
Publicado: (2015)

Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
por: Shujing Liu, et al.
Publicado: (2018)

Mutant-selective degradation by BRAF-targeting PROTACs
por: Shanique Alabi, et al.
Publicado: (2021)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Hima Patel, et al.
Publicado: (2021)

Author Correction: Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
por: Shujing Liu, et al.
Publicado: (2019)

Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas.
por: Elena González-Sánchez, et al.
Publicado: (2013)

Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules.
por: Jieun Koh, et al.
Publicado: (2013)

The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors.
por: Ashwin A Dihal, et al.
Publicado: (2013)

Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with <i>BRAF<sup>V600E</sup></i>-Mutant Advanced Papillary Thyroid Carcinoma
por: Eyun Song, et al.
Publicado: (2021)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
por: Jennifer A. Silver, et al.
Publicado: (2021)

BRAF Gene Mutation Analysis in Colorectal Cancer in South of Iran
por: Farshid Javadi, et al.
Publicado: (2014)

Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma
por: Tang HC, et al.
Publicado: (2015)

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling
por: Qing Yin, et al.
Publicado: (2019)

Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto’s Thyroiditis
por: Qin Zhang, et al.
Publicado: (2017)

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
por: Matthew J. Sale, et al.
Publicado: (2019)

Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency.
por: Megan C Hanna, et al.
Publicado: (2013)

Machine learning algorithm improved automated droplet classification of ddPCR for detection of BRAF V600E in paraffin-embedded samples
por: Gabriel A. Colozza-Gama, et al.
Publicado: (2021)

Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600 E/K mutated malignant melanomas
por: Sebastian Klein, et al.
Publicado: (2021)

Author Correction: A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening
por: Jrhau Lung, et al.
Publicado: (2021)

Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations
por: Raphaela Fritsche-Guenther, et al.
Publicado: (2018)

PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer
por: Gang Yang, et al.
Publicado: (2021)

Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case
por: Tian Yang, et al.
Publicado: (2021)

Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification
por: Sara Moreno, et al.
Publicado: (2021)

Author Correction: Machine learning algorithm improved automated droplet classification of ddPCR for detection of BRAF V600E in paraffin-embedded samples
por: Gabriel A. Colozza-Gama, et al.
Publicado: (2021)

Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAFV600E-driven human cancers
por: Yongxing Wu, et al.
Publicado: (2021)

Melanoma Targeted Therapies beyond <i>BRAF</i>-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
por: Karam Khaddour, et al.
Publicado: (2021)

Hole-in-one mutant phenotypes link EGFR/ERK signaling to epithelial tissue repair in Drosophila.
por: Jennifer A Geiger, et al.
Publicado: (2011)

Acta Nº600
por: Banco Central de Chile
Publicado: (2019)

Meet 600 HIGHWAYMEN
por: Emeline Jouve
Publicado: (2021)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
por: Antoni Ribas, et al.
Publicado: (2020)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Wolfram Samlowski, et al.
Publicado: (2021)

Clinicopathological Significance of BRAF (V600E), NRAS (Q61K) and TERT (C228T, C250T and SNP Rs2853669) Mutations in Bulgarian Papillary Thyroid Carcinoma Patients
por: Vidinov K., et al.
Publicado: (2021)

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
por: Maria Gonzalez-Cao, et al.
Publicado: (2021)

Targeting ERK induced cell death and p53/ROS-dependent protective autophagy in colorectal cancer
por: Wunan Mi, et al.
Publicado: (2021)

BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases
por: Najla Fakhruddin, et al.
Publicado: (2017)